Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on...

Keywords

DocetaxelRamucirumabMedicineInternal medicineHazard ratioRegimenLung cancerOncologyClinical endpointNeutropeniaPlaceboChemotherapyAdverse effectPerformance statusSurgeryRandomized controlled trialConfidence intervalPathology

Affiliated Institutions

Related Publications

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas , Igor Puzanov , Reinhard Dummer +33 more

2015 The Lancet Oncology 1528 citations

Publication Info

Year: 2014
Type: article
Volume: 384
Issue: 9944
Pages: 665-673
Citations: 1263
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1263

OpenAlex

Cite This

APA Style

                            
                                
                                    Edward B. Garon, 
                                
                                    Tudor‐Eliade Ciuleanu, 
                                
                                    Óscar Arrieta
                                
                                et al.
                            
                            (2014). 
                            Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. 
                            The Lancet
                            , 384
                            (9944)
                            , 665-673.
                            https://doi.org/10.1016/s0140-6736(14)60845-x
                        

Identifiers

DOI: 10.1016/s0140-6736(14)60845-x